Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

Aaron Hirschhorn wasn't just promoting another pet product when he took the Shark Tank stage in season 11. He was proposing a ground-breaking idea that would permanently alter veterinary care.

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Following a monthslong battle over CEO Anne Wojcicki’s plans to take 23andMe private, all seven independent members of its board resigned en masse Tuesday. The move is almost certainly the final ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

CEO Anne Wojcicki last spring proposed buying out the company and taking it private. From the San Francisco Business Times: Genetic testing pioneer 23andMe is looking at strategic alternatives ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations.